MultiCell Technologies Inc. Announces Strategic Initiatives For 2006 And 2007; Company To Focus On Advance Of First-in-Class Immune-Based Drug Candidates Into Advanced Phase Human Clinical Trials

SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. [OTCBB:MCET], developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, has announced its Strategic Initiatives for the remainder of 2006 and beyond. The announcement was made by Dr. Stephen Chang, President and Chief Executive Officer of MultiCell.

Back to news